Fighting overtreatment in adjuvant breast cancer therapy

The Lancet

Volumn 374, Issue 9707, 2009, Pages 2029-2030

  Gnant, Michael ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL RESEARCH; HUMAN; MEDICAL LITERATURE; METASTASIS; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT;

EID: 72049098788     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)62097-3     Document Type: Note

References (9)

1. Albain K.S., Barlow W.E., Ravdin P.M., et al., for The Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label randomised controlled trial. Lancet (2009) 10.1016/S0140-6736(09)61523-3 published online Dec 10.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
3. Gnant M., Mlineritsch B., Schippinger W., et al., for the ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360 (2009) 679-691
4. Del Mastro L., Dozin B., Aitini E., et al., other participants of the GONO-MIG group. Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group. Ann Oncol 19 (2008) 299-307
5. Coleman R., and Gnant M. New results from the use of bisphosphonates in cancer patients. Curr Opin Support Palliat Care 3 (2009) 213-218
6. Goldhirsch A., Ingle J.N., Gelber R.D., et al., Panel members. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20 (2009) 1319-1329
7. Dodwell D., Thorpe H., and Coleman R. Refining systemic therapy for early breast cancer: difficulties with subtraction. Lancet Oncol 10 (2009) 738-739
8. Albain K.S., Barlow W.E., Shak S., et al., for The Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 10.1016/S1470-2045(09)70314-6 published online Dec 10.
9. Sotiriou C., and Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 360 (2009) 790-800